These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 8335040)

  • 1. Pharmacokinetic and pharmacodynamic data and models in clinical trials.
    Steimer JL; Ebelin ME; Van Bree J
    Eur J Drug Metab Pharmacokinet; 1993; 18(1):61-76. PubMed ID: 8335040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of pharmacokinetic-pharmacodynamic relationships in drug development].
    Bellissant E; Courcier-Duplantier S; Blin O;
    Therapie; 2002; 57(4):347-57. PubMed ID: 12422555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A regulatory perspective on pharmacokinetic/pharmacodynamic modelling.
    Machado SG; Miller R; Hu C
    Stat Methods Med Res; 1999 Sep; 8(3):217-45. PubMed ID: 10636336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic relationships in phase I/phase II of drug development.
    Van Peer A; Snoeck E; Huang ML; Heykants J
    Eur J Drug Metab Pharmacokinet; 1993; 18(1):49-59. PubMed ID: 8335039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PK/PD modelling and simulations: utility in drug development.
    Rajman I
    Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.
    Colburn WA; Lee JW
    Clin Pharmacokinet; 2003; 42(12):997-1022. PubMed ID: 12959633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J; Green AR
    J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Facilitation of drug evaluation in children by population methods and modelling.
    Tod M; Jullien V; Pons G
    Clin Pharmacokinet; 2008; 47(4):231-43. PubMed ID: 18336053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic/pharmacodynamic modeling in drug research and development.
    Derendorf H; Lesko LJ; Chaikin P; Colburn WA; Lee P; Miller R; Powell R; Rhodes G; Stanski D; Venitz J
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1399-418. PubMed ID: 11185661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of population pharmacokinetics in drug development.
    Vozeh S; Steimer JL; Rowland M; Morselli P; Mentre F; Balant LP; Aarons L
    Clin Pharmacokinet; 1996 Feb; 30(2):81-93. PubMed ID: 8906893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic modelling: history and perspectives.
    Csajka C; Verotta D
    J Pharmacokinet Pharmacodyn; 2006 Jun; 33(3):227-79. PubMed ID: 16404503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and future directions of pharmacokinetic and pharmacokinetic-pharmacodynamic modelling and simulation: population approach group in Europe 19th annual meeting.
    Kloft C; Poggesi I
    Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1599-604. PubMed ID: 20969486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.
    Ayyar VS; Jusko WJ
    Pharmacol Rev; 2020 Apr; 72(2):414-438. PubMed ID: 32123034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated pharmacokinetics and pharmacodynamics in drug development.
    Dingemanse J; Appel-Dingemanse S
    Clin Pharmacokinet; 2007; 46(9):713-37. PubMed ID: 17713971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PK-PD integration and PK-PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology.
    Lees P; Giraudel J; Landoni MF; Toutain PL
    J Vet Pharmacol Ther; 2004 Dec; 27(6):491-502. PubMed ID: 15601443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.
    Dartois C; Brendel K; Comets E; Laffont CM; Laveille C; Tranchand B; Mentré F; Lemenuel-Diot A; Girard P
    Br J Clin Pharmacol; 2007 Nov; 64(5):603-12. PubMed ID: 17711538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.
    Derendorf H; Meibohm B
    Pharm Res; 1999 Feb; 16(2):176-85. PubMed ID: 10100300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.